Children's Hospital of Pittsburgh Annual Progress Report: 2011 Formula Grant
|
|
- Pamela Carter
- 5 years ago
- Views:
Transcription
1 Children's Hospital of Pittsburgh Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The Children's Hospital of Pittsburgh received $228,401 in formula funds for the grant award period January 1, 2012 through December 31, Accomplishments for the reporting period are described below. Research Project 1: Project Title and Purpose Regulatory T Cells and Tolerance after Blood and Marrow Transplantation Tolerance after blood and marrow transplantation (BMT) is achieved eventually in most patients after 1-2 years post-bmt as they become independent of drugs to avoid rejection or graft-versus-host-disease (GVHD). Regulatory T Cells (Tregs) are known to be important in sustaining tolerance, however, there is a great gap of knowledge after BMT in humans regarding their activity in disease state (GVHD) compared to health (tolerance). In this project we will isolate and analyze Tregs from patients experiencing GVHD and contrast these to Tregs isolated from patients free of GVHD. Once functional prerequisites for tolerance are discovered, novel targeted therapies can be devised for those patients who suffer from GVHD. Anticipated Duration of Project 1/1 / /31/2013 Project Overview Tolerance after blood and marrow transplantation (BMT) is achieved eventually in most patients after 1-2 years post-bmt as they become independent of pharmacological agents to avoid rejection or graft-versus-host-disease (GVHD). The hallmark of tolerance is unresponsiveness between host and graft tissues in the absence of any immunosuppressive (IS) drugs. Regulatory T Cells (Treg) expressing CD25 and FOXP3 were identified over 10 years ago as critical players in sustaining tolerance. More Tregs in the transplant graft itself or in the blood of BMT recipients is associated with less GVHD. However, beyond these numerical associations there is a great gap of knowledge regarding their functional profile and features in GVHD compared to those patients without it. The proposed studies would discover new biological characteristics of Tregs that are essential for tolerance as they suppress the function of conventional T cells (Tcon). In this project we will develop new assays to analyze Treg cells from BMT patients and contrast the functional features of Tregs purified from patients with or without GVHD including those who never had GVHD. These studies may identify new biomarkers for the presence or absence of GVHD and should also identify specific features of Treg cells that are prerequisites Children s Hospital of Pittsburgh 2011 Formula Grant Page 1
2 for suppressing Tcon to induce tolerance. A new in vitro model could become a valuable tool to monitor other autoimmune diseases as well. We propose two specific aims. Aim 1. Enumerate Tregs from patients longitudinally and determine their T Cell Receptor (TCR) diversity by spectratyping after purification based on the expression of FOXP3 and Helios transcription factors. Contrast the profile of Tregs between BMT recipients with and without GVHD. Aim 2. Design new functional assays to characterize and quantitate the biological profile and suppressive capacity of purified Tregs in vitro as they are mixed with conventional T cells from the same BMT recipient. Following non-specific and transplant recipient specific activation of Tregs and Tcon in the same co-cultures to model the in vivo scenario we will analyze Tregs by qpcr for cytokine and homing receptors, costimulatory and other critical suppressor molecules while Tcon cells will be tested in parallel for evidence of receiving suppressive signals. Principal Investigator Paul Szabolcs, MD Chief, Division of Blood and Marrow Transplantation and Cellular Therapy Children s Hospital of Pittsburgh of UPMC University of Pittsburgh School of Medicine Rangos Research Center, Room Penn Avenue Pittsburgh, PA Other Participating Researchers Xiaohua Chen, PhD Research Assistant Professor, Division of Blood and Marrow Transplantation and Cellular Therapy, CHP of UPMC, University of Pittsburgh Expected Research Outcomes and Benefits Graft-versus-host-disease (GVHD) is the most clinically significant immune mediated disease after allogeneic blood and marrow transplantation (BMT). If prevented or successfully treated, GVHD will be followed by tolerance characterized by the functional and peaceful co-existence of host and graft tissues in the absence of any immunosuppressive (IS) drugs. Despite prophylactic drug combinations, GVHD still develops in 20-60% of BMT recipients and can cause mortality in excess of 20% of all allogeneic transplant recipients notwithstanding significant morbidity and severe reduction in quality of life. There is preliminary evidence that rapid reconstitution of regulatory T Cells (Tregs) confers protection from GVHD in humans, nevertheless, there is a great gap of knowledge regarding their functional and biological features after transplant, beyond apparent numerical associations. In fact, the role of Tregs is far less well defined in human immune disorders compared to laboratory animal models. The proposed studies would identify and discover biological characteristics of Tregs that are essential for human transplant tolerance and thus new biomarkers of GVHD may be discovered. There are several centers that have developed ex vivo expansion platforms towards human clinical therapy with remarkably little functional knowledge of the manufactured products. Our studies could Children s Hospital of Pittsburgh 2011 Formula Grant Page 2
3 also aid to better define investigational products that are intended for human cell therapy trials. Importantly, a new in vitro laboratory model of testing Treg characteristics and function could become a valuable tool for researchers in the fields of rheumatology and gastroenterology to monitor disease activity and develop prognostic algorithms for autoimmune connective tissue disorders such as systemic lupus, Crohn s disease, rheumatoid arthritis, systemic sclerosis, diabetes, and others. Summary of Research Completed We are extremely grateful to the generous support to pursue our research goals as described in our two Aims below. We describe below the various aspects of our studies with the exciting new development on Treg cloning detailed in Aim I b below. Aim I. Aim 1A. Enumerate Treg cell distribution In our first interim report in July 2012, we presented our newly designed 8-color FACS panel to detect Treg phenotypes subsets. Since then, we have further optimized our FACS gating strategies to enhance detection of Treg sub-populations with the goal to correlate those with their functions. Figure 1 illustrates our current gating scheme. A P1 region identifies all lymphocytes (Figure 1a). Amongst P1 region cells, CD4+ cells were identified (P2) as shown in Figure 1b. Within this P2 region, putative Tregs were identified by gating on a CD25+ and CD127 dim subset as identifiable by the P3 region, see Figure 1c. The distribution of FoxP3 and Helios transcription factor expressing Tregs was then analyzed by quadratic gating, see Figure 1d. The distributions of naïve, central memory, and effector memory phenotype in each of the Treg subsets, as identified by their Foxp3/Helios expression, can be further subdivided by additional quadratic gating, see example for FoxP3+/Helios+ double positive Tregs in Figure 1e. The percentile to their parents of each population was applied, and thereby the influence from the variation of parent numbers was excluded in this analysis. To examine the state of Treg activation, we designed another 8-color FACS panel to include anti-ki67 (proliferation marker)/activated-caspase3 (apoptosis marker) Abs (Figure 1f). According to recent publications from Shimon Sakaguchi, we also added a combination of CD45RA vs Foxp3 to distinguish activated Tregs (region II) from resting Treg (region I) and Foxp3+ non-tregs (region III), see Figure 1g. With this new panel in place, we have characterized the distribution of Treg phenotypes in healthy donors. A total of seven healthy donors have been tested so far. An average of 8.8% CD4+CD25+CD127low Treg in CD4 population was observed. Notably, there were four populations carrying different Foxp3/Helios phenotypes (see Figure 1d) amongst the CD4+CD25+CD127low Treg, including single Helios+/FoxP3- (30.6%), double positive Foxp3+/Helios+ (39.3%), and single Foxp3+ /Helios- (8%) and double negative of Foxp3/Helios (22%). Circa 15% of CD4+CD25+CD127low Tregs and 13% of Foxp3+/Helios+ Tregs carried central memory phenotypes (CD45RO+CD62L+). Children s Hospital of Pittsburgh 2011 Formula Grant Page 3
4 Very recently, we started to monitor these phenotypes from patient samples. Pretransplant serotherapy by Alemtuzumab or ATG is routine in the allogeneic transplant population in our clinical practice; therefore we have a fairly low frequency of grade II or higher acute GvHD ( ~20%). Acute GVHD refers to GVHD that is diagnosed in the first ~ 100 days after transplant. With the relatively few patients, we have been able to test only one BMT recipient so far. As a comparison and control population, we have also examined cord blood recipients patients, some with mixed chimerism within the T cell fraction. A third population of patients, those with severe autoimmunity, was also enrolled on our IRB-approved protocol and tested. So far two cord blood recipients and three patients with autoimmunity have been studied. In comparison with healthy donors, there was no significant alteration in average numbers of CD4+CD25+CD127low (Figure 2A), single Foxp3+ (data not shown), and single Helios+ (data not shown) Tregs in the patients tested. However, we found, unexpectedly, a significant decrease of Foxp3+/Helios+ (double positive) Tregs carrying central memory phenotype (CD45RO+/CD62L+) in patients with autoimmunity, while this population showed a trend of increase in cord blood patients with mixed chimerism (Figure 2B). These results indicate that Foxp3+Helios+ central memory Tregs, rather than single Foxp3+ or Helios+ Tregs, may play an important role in the formation and maintenance of the immune tolerance. When we restrict the FACS analysis on the Sakaguchi regions (as defined by CD45RA/Foxp3 amongst CD4+/CD25 bright cells) and examine proliferation and apoptosis (Ki67/Caspase 3 respectively), we found that majority of Foxp3+Helios+ central memory Tregs (Figure 3A, 3B) belong to Sakaguchi region II -aka active Tregs which are CD45RA-/Foxp3 high (Q4-1 in Figure 3D). These cells have undergone significant proliferation, identifiable by the strong expression of Ki67 (see events in the Q1-1 quadrant in Figure 3C). When we examined the Treg profile of the subject with GVHD, we found little if any proliferation (low expression of Ki67 in Q1-2 Figure 4A) amongst Foxp3+/Helios+ Tregs, in comparison with that in a cord blood patient with mixed chimerism and in good clinical condition free of any GVHD, (Q1-2 Figure 4B). However, the overall total Treg numbers as identified by the CD4+CD25+CD127low phenotype were in normal range (data not shown). It is plausible that functional inefficacy of Foxp3+Helios+ Tregs and not their numerical paucity may be one reason for development of GVHD. Importantly, these new findings were detected directly from unmanipulated patient samples to reflect the human disease state without experimental influence leading to accidental bias. If the findings were confirmed with more cases, and Treg expansion would start with a defined phenotype it may lead to favorable response when treating GVHD by focusing on production of highly functional and stable Tregs. The findings on functionally and phenotypically distinct Tregs may also help to devise more powerful biomarker assays to predict the presence or absence of overall tolerance versus exaggerated/pathological immune responses (i.e., GVHD) post-hsct. Aim 1B. Treg single cell cloning Because Foxp3 and Helios genes are transcription factors it is not feasible to purify viable primary human Treg sub-populations by gating on these intracellular markers. Therefore, we Children s Hospital of Pittsburgh 2011 Formula Grant Page 4
5 have developed a novel single cell cloning technique with the goal to characterize Treg subpopulations. After expansion, we may sacrifice a fraction of the clone for characterization while many more are available for functional studies. The conventional method of T-cell cloning requires feeder cells to support single cell growth, which may cause contamination of unwanted cells or more likely lead to additional contact and soluble signals and might cause functional bias of Tregs expanding from single cells in this milieu. After months of pilot experiments, we have successfully established a new protocol for single Treg cloning without feeder cells (Figure 5), with a remarkable ~ 20% cloning efficiency for single Treg clones. To verify single cell clonality, we established TCR qpcr and TCR immunoscope for fast screening single cell cultures, another technical advance in this field. Figure 6 shows TCR qpcr profiles tested from the PBMC of a healthy donor (Figure 6A) or from the single cell cloning (Figure 6B); and TCR immunoscope profiles representing the PBMC of a healthy donor (Figure 6C) or the clonal progeny of a single cell (Figure 6D). Aim I C. TCR repertoire analysis Our original hypothesis was that the TCR repertoire of circulating Tregs from patients with GVHD would differ from that in patients not having experienced GVHD. The main obstacle to test this hypothesis has been the low cell numbers of Tregs that we have isolated, reflecting both CD4+ lymphopenia post transplant and the overall small volume of blood samples obtained from young children (4-8 ml range). Nevertheless, we have titrated the assay to the lowest cell number sufficient for efficient RNA purification. By adding carrier during the purification procedure, we can purify RNA from 1000 cells (data not shown). However, we have not yet obtained reproducibly clear signals on TCR immunoscope with RNA purified from 1000 cell. Aim II. After initially setting up a standard CFSE proliferation assay, we have performed further optimization to obtain differentiation peaks to give much distinct proliferation features. Figure 7 shows differentiation peaks generated at day 5 of a Tcon culture. We are currently titrating the dose of antigen presenting cells (APC), both live cells and artificial bead based signals, to determine the best conditions for in vitro Tcon activation to sufficiently quantitate the suppressive features from Treg. We have had surprising proliferative responses from Tregs in the presence of unnecessarily potent stimulatory signals. We are actively performing experiments to refine and enhance this functional assay with the inclusion of measuring the suppression of Th1 cytokine secretion of Tcon cells, particular IFNγ. In summary, by using our newly established 8-color FACS panels and gating strategy, we found preliminary evidence for the phenotypic shift of Foxp3+Helios+ central memory Tregs in the tested patient with acute GVHD (allogeneic responses), while the fraction of Tregs amongst CD4+ T cells remained in the normal range. In contrast, a trend in the increase of this T reg subset was seen in the two cord blood patients with mixed chimerism and no evidence of GVHD (allo-transplant tolerance). In the two tested cases of autoimmune disease, and no allogeneic cells in vivo, we found a significant decrease in the Foxp3+Helios+ central memory Tregs population. Children s Hospital of Pittsburgh 2011 Formula Grant Page 5
6 These findings suggest that Foxp3+Helios+ central memory Treg may play an important role in generation and maintain of immune tolerance. If confirmed, in sufficiently large patient groups, these are possibly exciting new findings. Importantly, the dataset was obtained directly from unmanipulated patient samples to accurately reflect the actual state of human disease such as GVHD and/or autoimmunity. If these very preliminary findings were to be confirmed in large datasets, it may guide the treatment of GVHD by focusing our attention on enhancing the number of functionally relevant Treg subsets rather than focusing on the composite total Treg pool. FIGURES Figure 1. FACS gating scheme for Treg phenotypes. Lymphocytes were identified in dotplots by FSC vs SSC (a); CD4+ cells were then gated (b). CD4+ T cells with CD25positivity and CD127 low expression were gated next (c). The distribution of Foxp3+ and Helios+ cells in CD4+CD25 high CD127 low Tregs were analyzed by quadratic gating (d). The distribution of CD45RO+/CD62L+ (central memory) versus other phenotypes in each Foxp3/Helios population were analyzed by additional quadratic gating (e); Ki67/Caspase 3 expression (f) and CD45R/Foxp3 (g) were also tested. Children s Hospital of Pittsburgh 2011 Formula Grant Page 6
7 Figure 2. The comparison of the distribution for CD4+CD25+CD127low population in CD4+ cells (A) or for Foxp3+Helios+ central memory Treg in CD4+CD25+CD127low cells (B) in healthy donors, in patients with autoimmunity or in patients with mixed chimerism and no evidence of autoimmunity or GVHD post-hsct. A B Figure 3. Characterization of Foxp3+Helios+Treg (A) with high expression of CD45RO+CD62L+ (B), and Ki67 (C); fell into Sakaguchi region II: CD45RA-Foxp3 high active Treg (D). A B C D Figure 4. Comparison of Ki67 expression of Foxp3+Helios+ Treg in a patient with agvhd (A) or with another healthy cord blood recipient in mixed chimerism (B) A B Children s Hospital of Pittsburgh 2011 Formula Grant Page 7
8 Figure 5. Single Treg clone expansion as reproduced by phase contrast inverted microscope at 7 days of culture (A) or at 12 days of culture (B). A B Figure 6. Identification of single cell clonality by TCRβ qpcr in single cell cloning (B) in comparison with PBMNC in a healthy donor (A); or by using TCR immunoscope in single cell cloning (D), in comparison with PBMNC obtained from a healthy volunteer donor (C). A B C D Children s Hospital of Pittsburgh 2011 Formula Grant Page 8
9 Figure 7. Differentiation peaks in CFSE proliferation assay are presented in dotplot (A) or in histogram (B). Children s Hospital of Pittsburgh 2011 Formula Grant Page 9
Altered regulatory T cell homeostasis in patients with CD4 + lymphopenia following allogeneic hematopoietic stem cell transplantation
Altered regulatory T cell homeostasis in patients with CD4 + lymphopenia following allogeneic hematopoietic stem cell transplantation Ken-ichi Matsuoka,, Robert J. Soiffer, Jerome Ritz J Clin Invest. 2010;120(5):1479-1493.
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationTolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
More informationS. No Topic Class No Date
S. No Topic Class No Date 1 Introduction 2 3 4 5 6 7 Fundamentals of Immunology Definitions and basic terms Types of immunity Organs of immune system Cells of immune system Innate immunity PAMPs PRRs Phagocytosis
More informationCD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells
CD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells Karin Pfisterer, Karoline M Lipnik, Erhard Hofer and Adelheid Elbe-Bürger Journal of Investigative Dermatology (2015)
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/23854 holds various files of this Leiden University dissertation. Author: Marel, Sander van der Title: Gene and cell therapy based treatment strategies
More informationImmune Reconstitution Following Hematopoietic Cell Transplant
Immune Reconstitution Following Hematopoietic Cell Transplant Patrick J. Kiel, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Indiana University Simon Cancer Center Conflicts of Interest Speaker Bureau
More informationSupplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).
Supplementary Figure Legends Supplemental Figure : Naïve T cells express Siglec-G. Splenocytes were isolated from WT B or Siglec-G -/- animals that have not been transplanted (n= per group) and analyzed
More informationT cell manipulation of the graft: Yes
T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor
More informationUsing Phosphoflow to Dissect Alterations in Cytokine- Induced Activation of Jak/STAT Pathway in Rheumatoid Arthritis
Using Phosphoflow to Dissect Alterations in Cytokine- Induced Activation of Jak/STAT Pathway in Rheumatoid Arthritis Molly Boland, Pathobiology and Molecular Medicine Mentors: Chander Raman, PhD S. Louis
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationSUPPLEMENT Supplementary Figure 1: (A) (B)
SUPPLEMENT Supplementary Figure 1: CD4 + naïve effector T cells (CD4 effector) were labeled with CFSE, stimulated with α-cd2/cd3/cd28 coated beads (at 2 beads/cell) and cultured alone or cocultured with
More informationUmbilical Cord Blood-Derived T Regulatory Cells
Umbilical Cord Blood-Derived T Regulatory Cells David H. McKenna, M.D. PACT Workshop - University of Pittsburgh May 5, 2008 Slide 1 Outline Overview of T regulatory (T R ) cells Potential for clinical
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationModulation of immunogenicity by engineered antigen-specific regulatory T cells: Fighting fire with fireman or police CARs
Modulation of immunogenicity by engineered antigen-specific regulatory T cells: Fighting fire with fireman or police CARs David W. Scott Department of Medicine Uniformed Services University of the Health
More informationImmune Regulation and Tolerance
Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationFrom Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us?
From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us? Sang Mo Kang, MD Qizhi Tang, PhD UCSF Division of Transplantation UCSF Transplant Conference 2012 The Reality of Immunosuppression
More informationTITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA
AD Award Number: DAMD17-01-1-0085 TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA PRINCIPAL INVESTIGATOR: ARTHUR A HURWITZ, Ph.d. CONTRACTING ORGANIZATION:
More informationAlessandra Franco, M.D., Ph.D. UCSD School of Medicine Department of Pediatrics Division of Allergy, Immunology and Rheumatology
Natural regulatory T cells recognize the heavy constant region (Fc) of immunoglobulins: a novel mechanism for IVIG immunotherapy in Pediatric Immune-mediated diseases Alessandra Franco, M.D., Ph.D. UCSD
More informationSEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationCentral tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)
More informationMechanisms of Immune Tolerance
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency
More informationSupplemental Figure 1. Protein L
Supplemental Figure 1 Protein L m19delta T m1928z T Suppl. Fig 1. Expression of CAR: B6-derived T cells were transduced with m19delta (left) and m1928z (right) to generate CAR T cells and transduction
More informationAdditional file 6. Summary of experiments characterizing development of adaptive immune response
Additional file 6. Summary of experiments characterizing development of adaptive immune response Tests performed to evaluate the development of adaptive immunity in patients are summarized in Table 1.
More information5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus
T cell precursors migrate from the bone marrow via the blood to the thymus to mature 1 2 The cellular organization of the thymus The proportion of thymus that produces T cells decreases with age 3 4 1
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors Presented by Jurg Rohrer, PhD, BD Biosciences 23-10780-00 Outline Introduction Cytokines Transcription
More informationImmunological alterations in mice irradiated with low doses
Immunological alterations in mice irradiated with low doses "Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary The structure of the immune system INNATE
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationFrom the Diagnostic Immunology Laboratories
Immunology Laboratories ISSUE 9 SPRING 2012 PAGE 1 Spring Meetings Please stop by and say hello in May at this year s American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting in New Orleans
More informationFluorochrome Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 CTLA-4 CTLA-4 CD15 CD3 FITC. Bio) PD-1 (MIH4, BD) ICOS (C398.4A, Biolegend) PD-L1 (MIH1, BD)
Additional file : Table S. Antibodies used for panel stain to identify peripheral immune cell subsets. Panel : PD- signaling; Panel : CD + T cells, CD + T cells, B cells; Panel : Tregs; Panel :, -T, cdc,
More informationTranscript-indexed ATAC-seq for immune profiling
Transcript-indexed ATAC-seq for immune profiling Technical Journal Club 22 nd of May 2018 Christina Müller Nature Methods, Vol.10 No.12, 2013 Nature Biotechnology, Vol.32 No.7, 2014 Nature Medicine, Vol.24,
More informationSupplementary Figure 1. Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Nature Immunology: doi: /ni.
Supplementary Figure 1 Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Expression of Mll4 floxed alleles (16-19) in naive CD4 + T cells isolated from lymph nodes and
More informationNaive, memory and regulatory T lymphocytes populations analysis
Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationCD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways
CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways Laura Strauss, Christoph Bergmann, Theresa L. Whiteside University
More informationDoes NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia
Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia Recognition of missing self HLA triggers lysis NK Inhibitory receptor Activating
More informationThe development of T cells in the thymus
T cells rearrange their receptors in the thymus whereas B cells do so in the bone marrow. The development of T cells in the thymus The lobular/cellular organization of the thymus Immature cells are called
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationTolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationWhat are bacteria? Microbes are microscopic(bacteria, viruses, prions, & some fungi etc.) How do the sizes of our cells, bacteria and viruses compare?
7.1 Microbes, pathogens and you Chp. 7 Lymphatic System & Immunity The interaction between microbes and humans? Microbes are very abundant in the environment and as well as in and on our bodies GOOD: We
More informationPage 4: Antigens: Self-Antigens The body has a vast number of its own antigens called self-antigens. These normally do not trigger immune responses.
Common Characteristics of B and T Lymphocytes Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Page 1: Introduction While B and T lymphocytes
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationSponsored document from Current Opinion in Immunology
Sponsored document from Current Opinion in Immunology T regulatory cells and the control of alloimmunity: from characterisation to clinical application Joanna Wieckiewicz, Ryoichi Goto, and Kathryn J Wood
More informationTh17 Pathway Research By Bio-Plex
Th17 Pathway Research By Bio-Plex Zhiyang Shen, Senior Product Manager Bio-Rad Laboratories, Inc 2011 年 6 月 28 日星期二 T helper cell research Timeline: advances on T helper research. Figure depicts some of
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors An encore presentation by Jurg Rohrer, PhD, BD Biosciences 10.26.10 Outline Introduction Cytokines
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationTolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
More informationSupplementary Figure S1: Alignment of CD28H. (a) Alignment of human CD28H with other known B7 receptors. (b) Alignment of CD28H orthologs.
Supplementary Figure S1: Alignment of CD28H. (a) Alignment of human CD28H with other known B7 receptors. (b) Alignment of CD28H orthologs. Predicted CD28H protein sequences from human, chimpanzee (pan
More informationAdoptive transfer strategies: impacting Tregs and vaccines. Carl June, M.D. Personalized Medicine
Adoptive transfer strategies: impacting Tregs and vaccines Personalized Medicine isbtc Oncology Biologics Development Primer Carl June, M.D. Professor of Pathology and Lab Medicine Abramson Cancer Center
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationHuman and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-10. Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald,
Human and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-1 Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald, James A. Dromey, Bo Han Lee, Junyan Qian, Ralph M Böhmer and Leonard
More informationHarnessing tolerance mechanisms with monoclonal antibodies Prof. Herman Waldmann
Harnessing tolerance mechanisms Herman Waldmann Sir William Dunn School of Pathology, Oxford University, UK 1 1. Transplantation 2 Lymphocyte depletion strategies to minimise drug immunosuppression in
More informationT Cell Development II: Positive and Negative Selection
T Cell Development II: Positive and Negative Selection 8 88 The two phases of thymic development: - production of T cell receptors for antigen, by rearrangement of the TCR genes CD4 - selection of T cells
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationThe central role of T helper cells
e central role of T helper s the expanding universe of lineages Cytometric analysis of T function Hyun-Dong Chang Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, Berlin, Germany CD8+ T
More informationx Lymphocyte count /µl CD8+ count/µl 800 Calculated
% Lymphocyte in CBC A. 50 40 30 20 10 Lymphocyte count /µl B. x10 3 2.5 1.5 C. 50 D. 1000 % CD3+CD8+ Cells 40 30 20 Calculated CD8+ count/µl 800 600 400 200 10 0 #61 #63 #64 #65 #68 #71 #72 #75 Figure
More informationAlessandra Franco MD PhD UCSD School of Medicine Department of Pediatrics Division of Allergy Immunology and Rheumatology
Immunodominant peptides derived from the heavy constant region of IgG1 stimulate natural regulatory T cells: identification of pan- HLA binders for clinical translation Alessandra Franco MD PhD UCSD School
More informationTHERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS. 9:40 am to 10:10 pm Laurence Cooper
THERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS 9:40 am to 10:10 pm Laurence Cooper ljncooper@ziopharm.com 05-16-2016 Forward-looking statements This presentation contains certain
More informationSupplementary Data. Treg phenotype
Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationT Cell Development. Xuefang Cao, MD, PhD. November 3, 2015
T Cell Development Xuefang Cao, MD, PhD November 3, 2015 Thymocytes in the cortex of the thymus Early thymocytes development Positive and negative selection Lineage commitment Exit from the thymus and
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationStart your T cell research right
Cell Isolation and Expansion Start your T cell research right Dynabeads tube-based cell isolation Cell Isolation and Expansion When you need healthy, pure, and viable T cells Dynabeads for human and mouse
More informationJanuary 25, 2017 Scientific Research Process Name of Journal: ESPS Manuscript NO: Manuscript Type: Title: Authors: Correspondence to
January 25, 2017 Scientific Research Process Name of Journal: World Journal of Gastroenterology ESPS Manuscript NO: 31928 Manuscript Type: ORIGINAL ARTICLE Title: Thiopurine use associated with reduced
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases
More informationKEY WORDS: CD4 1 CD25 1 regulatory T cells, IL-2, FOXP3, Donor lymphocyte infusion, Allogeneic hematopoietic stem cell transplantation
Combined CD4 1 Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3 1 Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation Emmanuel Zorn, Mehrdad Mohseni, Haesook
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationImmunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
More informationRapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
Research article Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells Chen Wang, 1 Tai Yi, 1 Lingfeng Qin, 2 Roberto A. Maldonado, 3 Ulrich H. von Andrian, 3
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-11-1-0294 TITLE: Modulation of Memory T Cells to Control Acquired Bone Marrow Failure PRINCIPAL INVESTIGATOR: Yi Zhang RECIPIENT: Temple University Philadelphia, PA 19140 REPORT DATE:
More informationObjectives. Abbas Chapter 11: Immunological Tolerance. Question 1. Question 2. Question 3. Definitions
Objectives Abbas Chapter 11: Immunological Tolerance Christina Ciaccio, MD Children s Mercy Hospitals and Clinics February 1, 2010 To introduce the concept of immunologic tolerance To understand what factors
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationSUPPLEMENTARY FIGURE 1
SUPPLEMENTARY FIGURE 1 A LN Cell count (1 ) 1 3 1 CD+ 1 1 CDL lo CD hi 1 CD+FoxP3+ 1 1 1 7 3 3 3 % of cells 9 7 7 % of cells CD+ 3 1 % of cells CDL lo CD hi 1 1 % of CD+ cells CD+FoxP3+ 3 1 % of CD+ T
More informationSupplemental Materials
Supplemental Materials Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability Qi Wang 1, Jianwei He 1, Dallas B. Flies 2, Liqun Luo
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationT Cell Receptor & T Cell Development
T Cell Receptor & T Cell Development Questions for the next 2 lectures: How do you generate a diverse T cell population with functional TCR rearrangements? How do you generate a T cell population that
More informationISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin
More informationManuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis
Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Vincent Laufer Rheumatology JC October 17 Disclosures NIH 2
More informationMECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More information